EVROF Stock Overview
Produces and sells dairy products in Greece. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Evrofarma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.86 |
| 52 Week High | €2.16 |
| 52 Week Low | €1.28 |
| Beta | 1.02 |
| 1 Month Change | 5.98% |
| 3 Month Change | 24.83% |
| 1 Year Change | 31.91% |
| 3 Year Change | 96.20% |
| 5 Year Change | 47.04% |
| Change since IPO | -64.35% |
Recent News & Updates
A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price
Dec 19
Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders
Oct 02Recent updates
A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price
Dec 19Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders
Oct 02Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%
Feb 29Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company
Jan 06Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled
Jan 05Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet
Dec 01Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital
Sep 15Is Evrofarma (ATH:EVROF) Using Too Much Debt?
May 27We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings
Oct 04Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture
May 19Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?
Feb 22Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital
Dec 29
Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?
Nov 22Shareholder Returns
| EVROF | GR Food | GR Market | |
|---|---|---|---|
| 7D | -6.5% | 0.3% | 2.2% |
| 1Y | 31.9% | 48.8% | 11.0% |
Return vs Industry: EVROF underperformed the Greek Food industry which returned 48.8% over the past year.
Return vs Market: EVROF exceeded the Greek Market which returned 11% over the past year.
Price Volatility
| EVROF volatility | |
|---|---|
| EVROF Average Weekly Movement | 6.7% |
| Food Industry Average Movement | 4.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in GR Market | 6.0% |
| 10% least volatile stocks in GR Market | 2.2% |
Stable Share Price: EVROF's share price has been volatile over the past 3 months compared to the Greek market.
Volatility Over Time: EVROF's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Greek stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 166 | Paschalis Papazilakis | www.evrofarma.gr |
Evrofarma SA produces and sells dairy products in Greece. It offers milk, yoghurt, and cheese products, as well as fermented beverages. The company also exports its products.
Evrofarma SA Fundamentals Summary
| EVROF fundamental statistics | |
|---|---|
| Market cap | €25.43m |
| Earnings (TTM) | €2.19m |
| Revenue (TTM) | €46.84m |
11.6x
P/E Ratio0.5x
P/S RatioIs EVROF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVROF income statement (TTM) | |
|---|---|
| Revenue | €46.84m |
| Cost of Revenue | €39.78m |
| Gross Profit | €7.06m |
| Other Expenses | €4.88m |
| Earnings | €2.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 15.08% |
| Net Profit Margin | 4.67% |
| Debt/Equity Ratio | 96.1% |
How did EVROF perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 13:14 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evrofarma SA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|